InMed Pharmaceuticals Inc.
For the period ended Jun 30, 2026. Filed Sep 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Sep 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Part III
The information required by Part III is omitted from this report because we will file a definitive proxy statement (the “2026 Proxy Statement”) for our 2026 annual general and special meeting of shareholders within 120 days after the end of our 2026 fiscal year pursuant to Regulation 14A of the Exchange Act. If the 20265 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report, the omitted information will be included in an amendment to this Annual Report filed not later than the end of such 120-day period.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.